Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib

Propanc plans to move PRP into a first-in-human study expected to enroll up to 50 patients with advanced solid tumors.

Rhea-AI Summary

Propanc Biopharma (PPCB) reported preclinical pancreatic cancer results for PRP, including more than 90% mean tumor growth inhibition versus vehicle.

In advanced pancreatic ductal adenocarcinoma models, intravenous PRP extended median overall survival more than 2.5-fold versus controls, reduced liver and peritoneal metastases, and reduced fibrosis and markers of epithelial-mesenchymal transition, a change in cell behavior. Chemotherapy-resistant cells became more sensitive to gemcitabine plus nab-paclitaxel. PRP has FDA orphan drug designation for pancreatic cancer. Propanc sees it as a potential combination or sequential partner, rather than a substitute, for the FDA-approved RAS inhibitor daraxonrasib.

The company plans a Phase 1b first-in-human study in Q1 2027, expected to enroll up to 50 advanced solid-tumor patients across Australia. Prior compassionate-use observations involved related proenzyme formulations.

10 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate point. Forward-looking: it has not happened yet and may not happen.Phase 1b first-in-human study is planned for Q1 2027, with up to 50 patients expected.
• Minor pointPRP mean tumor growth inhibition exceeded 90% versus vehicle in advanced pancreatic cancer models (p < 0.001).
• Minor pointMedian overall survival extended more than 2.5-fold versus controls in advanced pancreatic cancer animal models.
• Minor pointLiver and peritoneal metastatic burden declined in PRP-treated pancreatic cancer models.
• Minor pointTumor microenvironment remodeling included lower cancer-associated fibroblast activity, less fibrosis, and suppressed epithelial-mesenchymal transition markers.

5 minor points

• Minor pointChemotherapy-resistant pancreatic cancer cells showed greater sensitivity to gemcitabine plus nab-paclitaxel.
• Minor pointRelated proenzyme formulations showed prolonged-survival signals in limited prior compassionate-use experience with advanced solid-tumor patients.
• Minor pointNo severe treatment-related adverse events were reported in that limited compassionate-use experience with related formulations.
• Minor pointFDA orphan drug designation is held by PRP for pancreatic cancer treatment.
• Minor point. Forward-looking: it has not happened yet and may not happen.Potential combination or sequential use with daraxonrasib is Propanc’s stated direction for PRP, not replacement.

Negative

• None.

Key Figures

Tumor growth inhibition: >90% P-value: p < 0.001 Median overall survival extension: >2.5-fold +2 more

Tumor growth inhibition

>90%

Mean inhibition versus vehicle in advanced PDAC models

P-value

p < 0.001

PRP tumor-growth inhibition versus vehicle

Median overall survival extension

>2.5-fold

PRP-treated advanced PDAC models versus controls

Planned study start

First quarter of 2027

Multicenter, open-label Phase 1b first-in-human study

Planned enrollment

Up to 50 patients

Advanced solid tumors, including pancreatic, ovarian, and refractory prostate cancers

Historical Context

2 past events · Latest: Sep 22

2 events

1. Sep 22

   PRP preclinical data

   24h Move

   +3.4%

   Reported over 90% tumor-growth inhibition and over 2.5-fold median survival extension in PDAC models.

2. Aug 27

   PRP preclinical data

   24h Move

   +109.3%

   Reported over 90% tumor-growth inhibition and over 2.5-fold median survival extension in PDAC models.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

pdac, epithelial-mesenchymal transition, hazard ratio, xenograft, +1 more

5 terms

pdac medical

"pancreatic ductal adenocarcinoma (PDAC)"

PDAC stands for pancreatic ductal adenocarcinoma, the most common and aggressive form of pancreatic cancer that starts in the pancreas’s duct cells. It matters to investors because PDAC represents a large unmet medical need with high patient mortality, driving intense drug development, clinical trial activity and potential regulatory milestones—like a critical, hard-to-fix engine part whose failure creates urgent demand for effective solutions, affecting a company’s valuation and risk profile.

epithelial-mesenchymal transition medical

"epithelial-mesenchymal transition (EMT), cancer stem cells, fibrosis"

A biological process in which normally stationary, tightly connected cells change into a more flexible, mobile state that lets them move and invade other tissues, like bricks in a wall turning into travelers. For investors, it matters because this behavior can drive disease aggressiveness, treatment resistance and influence which drug targets and diagnostic tests are valuable, affecting clinical trial success, commercial prospects and company valuations.

hazard ratio medical

"median overall survival of 13.2 months versus 6.6 months with chemotherapy (hazard ratio 0.40)"

A hazard ratio is a way scientists compare the chance of something happening over time between two groups, like patients taking different medicines. If the ratio is high, it means one group is more likely to experience the event sooner or more often, which helps determine how effective a treatment is or how risky a situation might be.

xenograft medical

"orthotopic and patient-derived xenograft models of advanced PDAC"

A xenograft is biological tissue or cells taken from one species and placed into another, most commonly human tumor cells implanted into laboratory animals to study disease or test drugs. Investors watch xenograft results because they serve like a controlled dress rehearsal for a therapy: positive responses in these models can de‑risk programs, attract funding or partnerships, and influence the likelihood and timing of clinical trials and regulatory milestones.

intent-to-treat medical

"Results in the intent-to-treat population were consistent"

A method for analyzing clinical trial results that counts every participant in the group they were originally assigned to, regardless of whether they completed the treatment or followed instructions. Like grading a class by the seats students were assigned rather than who finished the exam, it preserves the trial’s original comparisons and gives a realistic, often more conservative, estimate of how a drug or device performs in real-world use — information investors use to judge reliability and regulatory risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Preclinical package also shows more than 2.5-fold survival extension in advanced PDAC models; Company contrasts a non-RAS, differentiation-based mechanism with the clinical benchmark set by RASONQUE (daraxonrasib)

MELBOURNE, Australia, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today highlighted new preclinical data for its lead candidate PRP in pancreatic ductal adenocarcinoma (PDAC) and compared that profile with a clinical standard recently established by Revolution Medicines, Inc.

On August 26, 2026, the U.S. Food and Drug Administration approved daraxonrasib (RASONQUE), Revolution Medicines’ oral RAS(ON) multi-selective inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy, or who are not candidates for multiagent systemic therapy. Approval was based on the Phase 3 RASolute 302 trial. In the RAS G12 population, daraxonrasib delivered median overall survival of 13.2 months versus 6.6 months with chemotherapy (hazard ratio 0.40), median progression-free survival of 7.3 months versus 3.5 months (hazard ratio 0.45), and a confirmed objective response rate of 33.2% versus 11.8%. Results in the intent-to-treat population were consistent: median overall survival 13.2 versus 6.7 months (hazard ratio 0.40) and median progression-free survival 7.2 versus 3.6 months (hazard ratio 0.49).

Those data validate RAS as a druggable driver in a disease in which RAS mutations are present in roughly 90% of cases. They also leave a defined residual problem: epithelial-mesenchymal transition (EMT), cancer stem cells, fibrosis, and metastatic dissemination are not the primary targets of RAS pathway blockade.

PRP is a proprietary intravenous fixed-ratio combination of the pancreatic proenzymes, trypsinogen and chymotrypsinogen (1:6). It does not inhibit RAS. In orthotopic and patient-derived xenograft models of advanced PDAC, three-times-weekly intravenous PRP produced:

• >90%, mean, tumor growth inhibition, versus vehicle (p < 0.001), building on previously reported inhibition above 85%.
• A marked reduction in metastatic burden in the liver and peritoneum.
• Remodeling of the tumor microenvironment, including lower cancer-associated fibroblast activity, less fibrosis, and suppression of EMT markers.
• Greater sensitivity of chemo-resistant PDAC cells to gemcitabine plus nab-paclitaxel, supporting the potential for lower chemotherapy doses with improved activity.
• A median overall survival extension of more than 2.5-fold versus controls.
  
  

Limited prior compassionate-use experience with related proenzyme formulations has shown signals of prolonged survival in advanced solid-tumor patients, with a favorable safety profile and no severe treatment-related adverse events reported in that experience. PRP holds FDA Orphan Drug Designation Status for the treatment of pancreatic cancer and is not restricted to the RAS genotype.

“Daraxonrasib is a genuine advancement for patients with metastatic pancreatic cancer, and the RASolute 302 survival benefit is the clinical benchmark the field now has to beat or complement,” said James Nathanielsz, Propanc’s Chief Executive Officer. “PRP is aimed at a different node. The preclinical package — deep tumor control, fewer metastases, a less fibrotic microenvironment, and chemo re-sensitization — is the biology RAS inhibition does not directly address. We see PRP as a potential combination or sequential partner, not a substitute, and we are moving it into patients.”

The Company plans to start a multicenter, open-label Phase 1b first-in-human study of PRP in the first quarter of 2027. The study is expected to enroll up to 50 patients with advanced solid tumors, including pancreatic, ovarian, and refractory prostate cancers, at sites across Australia.

Comparative Summary

Attribute	PRP	Daraxonrasib / RASONQUE
Modality	IV proenzyme combination (trypsinogen + chymotrypsinogen, 1:6)	Oral RAS(ON) multi-selective inhibitor
Primary biology	Differentiation, EMT reversal, cancer stem cells, fibrosis, metastasis	Oncogenic RAS(ON) signaling
Stage	Preclinical PDAC plus clinical efficacy evaluated in advanced cancer patients on compassionate grounds; Phase 1b planned Q1 2027	FDA-approved August 26, 2026; Phase 3 RASolute 302
PDAC activity reported	>90% mean tumor-growth inhibition; >2.5-fold median survival in animal models; reduced liver and peritoneal metastases	mOS 13.2 vs 6.6–6.7 months; mPFS 7.2–7.3 vs 3.5–3.6 months; ORR ~32% vs ~12%
Genotype	Not RAS-mutation restricted; FDA Orphan Drug Designation Status in pancreatic cancer	FDA Approved in metastatic pancreatic adenocarcinoma after prior therapy, activity shown across RAS G12 and overall populations

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.

More information: www.propanc.com

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

Company:
Propanc Biopharma, Inc.
James Nathanielsz

+61-3-9882-0780

info@propanc.com

Investor Contact:

irteam@propanc.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Propanc Biopharma’s PRP pancreatic cancer studies show?

PRP produced more than 90% mean tumor growth inhibition versus vehicle and more than 2.5-fold median overall survival extension versus controls in advanced pancreatic cancer models. The studies also showed reduced liver and peritoneal metastases and greater sensitivity of chemotherapy-resistant cells to gemcitabine plus nab-paclitaxel.

When does Propanc Biopharma plan to start its PRP human trial?

Propanc plans to start a multicenter, open-label Phase 1b first-in-human study in Q1 2027. The study is expected to enroll up to 50 patients with advanced solid tumors, including pancreatic, ovarian, and refractory prostate cancers, at sites across Australia.

How was PRP administered in Propanc Biopharma’s pancreatic cancer models?

PRP was administered intravenously three times weekly in orthotopic and patient-derived xenograft models of advanced pancreatic ductal adenocarcinoma. It is a fixed-ratio combination of the pancreatic proenzymes trypsinogen and chymotrypsinogen at 1:6, and does not inhibit RAS.